Skip to main content

Published locations for Atezolizumab doubles survival of NSCLC patients with poor performance status

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Atezolizumab doubles survival of NSCLC patients with poor performance status

User login

  • Reset your password
  • /content/atezolizumab-doubles-survival-nsclc-patients-poor-performance-status
  • /fedprac/article/258024/lung-cancer/atezolizumab-doubles-survival-nsclc-patients-poor-performance
  • /internalmedicinenews/article/258024/lung-cancer/atezolizumab-doubles-survival-nsclc-patients-poor
  • /oncologypractice/article/258024/lung-cancer/atezolizumab-doubles-survival-nsclc-patients-poor
  • /fedprac/avaho/article/258024/lung-cancer/atezolizumab-doubles-survival-nsclc-patients-poor
  • /hematology-oncology/article/258024/lung-cancer/atezolizumab-doubles-survival-nsclc-patients-poor
  • /internalmedicine/article/258024/lung-cancer/atezolizumab-doubles-survival-nsclc-patients-poor
  • /chestphysician/article/258024/lung-cancer/atezolizumab-doubles-survival-nsclc-patients-poor